Optimization of Versatile Oxindoles as Selective PI3Kδ Inhibitors

被引:11
|
作者
Methot, Joey L. [1 ]
Achab, Abdelghani [1 ]
Christopher, Matthew [1 ]
Zhou, Hua [1 ]
McGowan, Meredeth A. [1 ]
Trotter, B. Wesley [1 ]
Fradera, Xavier [2 ]
Lesburg, Charles A. [2 ]
Goldenblatt, Peter [3 ]
Hill, Armetta [3 ]
Chen, Dapeng [4 ]
Otte, Karin M. [4 ]
Augustin, Martin [5 ]
Shah, Sanjiv [3 ]
Katz, Jason D. [1 ]
机构
[1] Merck & Co Inc, Discovery Chem, Boston, MA 02115 USA
[2] Merck & Co Inc, Computat & Struct Chem, Boston, MA 02115 USA
[3] Merck & Co Inc, In Vitro Pharmacol, Boston, MA 02115 USA
[4] Merck & Co Inc, Pharmacokinet Pharmacodynam & Drug Metab, Boston, MA 02115 USA
[5] Proteros Biostruct, D-82152 Martinsried, Germany
来源
ACS MEDICINAL CHEMISTRY LETTERS | 2020年 / 11卷 / 12期
关键词
PI3K delta inhibitor; PI3K alpha selectivity; oxindole; adenosine uptake; CHRONIC LYMPHOCYTIC-LEUKEMIA; INDUCED VASCULAR INJURY; PI3K INHIBITORS; IN-VITRO; CD69; MECHANISMS; RESPONSES; POTENCY;
D O I
10.1021/acsmedchemlett.0c00441
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The 3,3-disubstituted oxindole moiety is a versatile and rigid three-dimensionally shaped scaffold. When engineered with a purine hinge-binding core, exceptionally selective PI3K delta kinase inhibitors were discovered by exploiting small differences in isoform selectivity pockets. Crystal structures of early lead 2f bound to PI3K delta and PI3K alpha helped rationalize the high selectivity observed with 2f. By attenuating the lypophilicity and metabolic liabilities of an oxindole moiety, we improved the preclinical species PK and solubility and reduced adenosine uptake activity. The excellent potency and kinome selectivity of 7-azaoxindole 4d and spirooxindole 5d, together with a low plasma clearance and good half-life in rat and dog, supported a low once-daily predicted human dose.
引用
收藏
页码:2461 / 2469
页数:9
相关论文
共 50 条
  • [1] Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors
    Jia, Hong
    Dai, Guangxiu
    Su, Weiguo
    Xiao, Kun
    Weng, Jianyang
    Zhang, Zhulin
    Wang, Qing
    Yuan, Tianhai
    Shi, Fuying
    Zhang, Zheng
    Chen, Wei
    Sai, Yang
    Wang, Jian
    Li, Xiong
    Cai, Yu
    Yu, Jun
    Ren, Ping
    Venable, Jennifer
    Rao, Tadimeti
    Edwards, James P.
    Bembenek, Scott D.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (10) : 4936 - 4948
  • [2] Designing selective PI3K inhibitors
    Crunkhorn, Sarah
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (02) : 105 - 105
  • [3] Designing selective PI3K inhibitors
    Sarah Crunkhorn
    [J]. Nature Reviews Drug Discovery, 2010, 9 : 105 - 105
  • [4] Discovery and optimization of heteroaryl piperazines as potent and selective PI3Kδ inhibitors
    Zhou, Hua
    McGowan, Meredeth A.
    Lipford, Kathryn
    Christopher, Matthew
    Fradera, Xavier
    Witter, David
    Lesburg, Charles A.
    Li, Chaomin
    Methot, Joey L.
    Lampe, John
    Achab, Abdelghani
    Shaffer, Lynsey
    Goldenblatt, Peter
    Shah, Sanjiv
    Bass, Alan
    Schroeder, Gottfried
    Chen, Dapeng
    Zeng, Haoyu
    Augustin, Martin A.
    Katz, Jason D.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2020, 30 (01)
  • [5] Discovery and Optimization of Pyridazinones as PI3Kδ Selective Inhibitors for Administration by Inhalation
    Bruno, Paolo
    Micoli, Alessandra
    Corsi, Mauro
    Pala, Daniele
    Guariento, Sara
    Fiorelli, Claudio
    Ronchi, Paolo
    Fioni, Alessandro
    Gallo, Paola Maria
    Marenghi, Giulia
    Bertolini, Serena
    Capacchi, Silvia
    Mileo, Valentina
    Biagetti, Matteo
    Capelli, Anna Maria
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2024,
  • [6] Discovery of Potent and Selective PI3Kγ Inhibitors
    Drew, Samuel L.
    Thomas-Tran, Rhiannon
    Beatty, Joel W.
    Fournier, Jeremy
    Lawson, Kenneth, V
    Miles, Dillon H.
    Mata, Guillaume
    Sharif, Ehesan U.
    Yan, Xuelei
    Mailyan, Artur K.
    Ginn, Elaine
    Chen, Jie
    Wong, Kent
    Soni, Divyank
    Dhanota, Puja
    Chen, Pei-Yu
    Shaqfeh, Stefan G.
    Meleza, Cesar
    Pham, Amber T.
    Chen, Ada
    Zhao, Xiaoning
    Banuelos, Jesus
    Jin, Lixia
    Schindler, Ulrike
    Walters, Matthew J.
    Young, Stephen W.
    Walker, Nigel P.
    Leleti, Manmohan Reddy
    Powers, Jay P.
    Jeffrey, Jenna L.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (19) : 11235 - 11257
  • [7] Discovery and optimization of pyrimidone PI3Kβ inhibitors
    Halley, Frank
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
  • [8] Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors
    Ma, Chen-Chen
    Zhang, Cheng-Mei
    Tang, Long-Qian
    Liu, Zhao-Peng
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 151 : 9 - 17
  • [9] PI3K Isoform-Selective Inhibitors in Cancer
    Duncan, Leslie
    Shay, Chloe
    Teng, Yong
    [J]. SINGLE-CELL SEQUENCING AND METHYLATION: METHODS AND CLINICAL APPLICATIONS, 2020, 1255 : 165 - 173
  • [10] Development of novel, selective and irreversible PI3Kδ inhibitors
    Dalton, Samuel
    Campos, Sebastien
    Bush, Jacob
    Thomas, Daniel
    Convery, Maire
    Murphy, John
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252